These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8857548)

  • 1. Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells.
    Hiddemann W; Schleyer E; Unterhalt M; Kern W; Büchner T
    Ther Drug Monit; 1996 Aug; 18(4):341-9. PubMed ID: 8857548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells.
    Hiddemann W; Schleyer E; Unterhalt M; Zühlsdorf M; Rolf C; Reuter C; Kewer U; Uhrmeister C; Wörmann B; Büchner T
    Leukemia; 1992 Dec; 6(12):1273-80. PubMed ID: 1453772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma.
    Wiley JS; Taupin J; Jamieson GP; Snook M; Sawyer WH; Finch LR
    J Clin Invest; 1985 Feb; 75(2):632-42. PubMed ID: 3871794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.
    Lindner LH; Ostermann H; Hiddemann W; Kiani A; Würfel M; Illmer T; Karsch C; Platzbecker U; Ehninger G; Schleyer E
    Int J Hematol; 2008 Nov; 88(4):381-386. PubMed ID: 18836794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activity.
    Braess J; Voss S; Jahns-Streubel G; Schoch C; Haferlach T; Kern W; Keye S; Schleyer E; Hiddemann W
    Br J Haematol; 2000 Jul; 110(1):170-9. PubMed ID: 10930995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
    Braess J; Wegendt C; Jahns-Streubel G; Kern W; Keye S; Unterhalt M; Schleyer E; Hiddemann W
    Br J Haematol; 2000 May; 109(2):388-95. PubMed ID: 10848830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside.
    Preisler HD; Rustum YM; Azarnia N; Priore R
    Cancer Chemother Pharmacol; 1987; 19(1):69-74. PubMed ID: 3815728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukaemic blasts differ from normal bone marrow mononuclear cells and CD34+ haemopoietic stem cells in their metabolism of cytosine arabinoside.
    Braess J; Wegendt C; Feuring-Buske M; Riggert J; Kern W; Hiddemann W; Schleyer E
    Br J Haematol; 1999 May; 105(2):388-93. PubMed ID: 10233409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of high-dose cytarabine and its deamination product--a reappraisal.
    Burk M; Heyll A; Arning M; Volmer M; Fartash K; Schneider W
    Leuk Lymphoma; 1997 Oct; 27(3-4):321-7. PubMed ID: 9402329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics.
    Braess J; Freund M; Hanauske A; Heil G; Kaufmann C; Kern W; Schüssler M; Hiddemann W; Schleyer E
    Leukemia; 1998 Oct; 12(10):1618-26. PubMed ID: 9766508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells.
    Jamieson GP; Snook MB; Wiley JS
    Leuk Res; 1990; 14(5):475-9. PubMed ID: 2345470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison.
    Hiddemann W; Schleyer E; Uhrmeister C; Aul CH; Maschmeyer G; Heinecke A; Büchner T
    Cancer Treat Rev; 1990 Sep; 17(2-3):279-85. PubMed ID: 2272043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long intracellular retention of 4'-thio-arabinofuranosylcytosine 5'-triphosphate as a critical factor for the anti-solid tumor activity of 4'-thio-arabinofuranosylcytosine.
    Someya H; Waud WR; Parker WB
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):772-80. PubMed ID: 16180016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytidine deaminase - the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells.
    Braess J; Pförtner J; Kern W; Hiddemann W; Schleyer E
    Ann Hematol; 1999 Nov; 78(11):514-20. PubMed ID: 10602895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia.
    Preisler HD; Rustum Y; Priore RL
    Eur J Cancer Clin Oncol; 1985 Jan; 21(1):23-30. PubMed ID: 4038655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor.
    Reuter C; Auf der Landwehr U; Schleyer E; Zühlsdorf M; Ameling C; Rolf C; Wörmann B; Büchner T; Hiddemann W
    Leukemia; 1994 Feb; 8(2):217-25. PubMed ID: 8309245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transport and metabolism of 1-beta-D-arabinofuranosylcytosine in human ovarian adenocarcinoma cells.
    Jamieson GP; Snook MB; Bradley TR; Bertoncello I; Wiley JS
    Cancer Res; 1989 Jan; 49(2):309-13. PubMed ID: 2910450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytosine arabinoside in the treatment of T-cell acute lymphoblastic leukemia.
    Wiley JS; Woodruff RK; Jamieson GP; Firkin FC; Sawyer WH
    Aust N Z J Med; 1987 Aug; 17(4):379-86. PubMed ID: 3501710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia.
    Wiley JS; Jones SP; Sawyer WH; Paterson AR
    J Clin Invest; 1982 Feb; 69(2):479-89. PubMed ID: 6948829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous determination of cytosine arabinoside and its metabolite uracil arabinoside in human plasma by LC-MS/MS: Application to pharmacokinetics-pharmacogenetics pilot study in AML patients.
    Donnette M; Solas C; Giocanti M; Venton G; Farnault L; Berda-Haddad Y; Hau LTT; Costello R; Ouafik L; Lacarelle B; Ciccolini J; Fanciullino R
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Sep; 1126-1127():121770. PubMed ID: 31454720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.